HealthcareLarge capRs 35,974 crRs 130.4 cr traded a dayPharmaceuticals
Close on 10 September 2026
2,220.60
−1.25%
52-week range98% of the way up
1,100.302,248.80
Market cap
35,974 cr
P/E (TTM)
102.2×
industry 45×
EPS (TTM)
21.73
Revenue YoY
+25.7%
Q1 FY27
Net margin
11.5%
+13.7pt vs a year ago
Growth trend
-12.1pt
vs last quarter’s YoY
1 month
+20.2%
Below 52w high
1.3%
RSI (14)
75
overbought
Daily swing
3.9%
average true range
Volume
0.7×
vs 20-day average
Traded
Rs 130 cr
median day
Close200-day averageMaterial filing
260 sessions · hover for the filing behind a move
Key metrics
each ranked against every stock scanned tonight
Above the 200-day average
Top of the universe
+38.9%
One-year return
Top of the universe
+49.9%
Return on capital employed
Bottom of the universe
5.6%
Debt to equity
Below the median
0.43×
Profitable quarters, last four
of the last four reported
4 of 4
Cash conversion
cash from operations against reported profit
111%
Revenue growth, year on year
latest reported quarter
+25.7%
Below the 52-week high
from the highest close of the year
-1.3%
1 week
+13.84%
1 month
+20.20%
3 months
+16.41%
6 months
+82.68%
1 year
+49.93%
The read
written from the numbers on this page
The evidence leans constructive8 supporting, 2 against, 1 worth knowing
Supporting
trading 39% above its 200-day average
sitting at 98% of its 52-week range, with little overhead supply from trapped buyers
up 50% over twelve months
matches profit that turns into cash, which has beaten the market by +2.73 points over 20 sessions across 9,184 past signals
9 of the scans it matches have a positive measured record
6 independent kinds of evidence agree today, which is uncommon
revenue grew 26% year on year in the quarter ending 30 June 2026
net margin has widened from 2.8% to 11.5% across four quarters
Against
2 of the scans it matches have historically underperformed the market
priced at 102× earnings against an industry median of 45× — 129% above its peers
Worth knowing
RSI at 75 is stretched; strong stocks stay stretched for a long time, so this is a note on entry timing, not on direction
WOCKPHARMA sits in Pharmaceuticals — worth checking whether the whole group is moving together or whether this name is doing it alone.
What would change this read: a close below 1,599, its 200-day average; a failure to hold the top of its 52-week range.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.
What is working, what is not
from the filings and from the price, with the figure behind every line
Working8
Net margin improved from -2.0% to 11.5%.
-2.0%11.5%
Profit rose year on year in all 4 of the last 4 quarters.
4
Operating cash flow was Rs 390 cr against Rs 352 cr of profit, which is 111% of it.
Rs 390 crRs 352 cr111%
Trading 38.9% above its 200-day average, which is the line most investors use to separate a bull phase from a bear one.
+38.9%
Within 1.3% of its 52-week high.
-1.3%
Up 49.9% over the past year.
+49.9%
4 different kinds of evidence point at it tonight, not 4 versions of the same one.
4 families
Rs 130 crore changes hands on a median day, so an ordinary order is not the reason it moves.
Rs 130 cr
Needs watching
Nothing on this side tonight — not in the filings and not in the price.
Every figure here is computed — from the company’s own filings, or from its own closing prices. Wording of 3 of these 3 filing lines was drafted by a language model, which is given the figures and may not introduce another — any sentence containing a number that did not come from the filings is discarded before it reaches this page.
How it has performed
price return over each window, beside the median NSE stock over the same days
What the scans say today
16 of 47 matched on 10 Sep
WOCKPHARMA matches 16 of the 47 scans today, across 6 different kinds of evidence. Three or more independent families agreeing is uncommon — it is the same test the shortlist on every page uses.
Return on capital uses profit before tax over equity plus borrowings. The textbook version adds finance costs back; those are not tagged reliably in quarterly filings, so this understates the ratio for a heavily borrowed company rather than flattering it. Balance sheets are filed half-yearly, so these can be up to six months behind the profit figures above.
Valuation against its own history
105 sessions since 16 March 2026
87×
median 132×
393×
now 102×
WOCKPHARMA trades at 102× trailing earnings, below its median of 132× over this window — 22% less expensive than usual. The band runs from the 5th to the 95th percentile, so single-day spikes do not set the edges.
This window is short by the standards of valuation history — it begins where four quarters of filed earnings first exist. A stock can look cheap against two years and expensive against ten.
Order win filings were typically -0.10pt vs the market over the next 5 sessions (n=630) · Other filing filings were typically +0.01pt vs the market over the next 5 sessions (n=17,202) · AGM / EGM filings were typically +0.17pt vs the market over the next 5 sessions (n=8,423)
The business
from the company’s filed results
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.
Going for it
revenue grew 26% against the same quarter a year earlier
Going against it
profit dropped 769% year on year
net margin narrowed from 17.0% to 11.5%
Quarter-by-quarter numbers, as filed
Quarter
Revenue
Profit before tax
Net profit
EPS
Net margin
Q1 FY27
30 Jun · consolidated
929
116
107
6.55
11.5%
Q4 FY26
31 Mar · consolidated
965
189
164
10.23
17.0%
Q3 FY26
31 Dec · consolidated
888
67
61
3.61
6.9%
Q3 FY25
31 Dec · consolidated
721
21
20
0.91
2.8%
Q2 FY25
30 Sep · consolidated
809
-9
-16
-1.47
-2.0%
Q1 FY25
30 Jun · consolidated
739
-6
-16
-0.95
-2.2%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.
Where the price stands
the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average+15.0%
Versus 200-day average+38.9%
Below 52-week high-1.3%
Above 52-week low+101.8%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)74.5
Higher closes in last 54 of 5
Six-month return+82.68%
Risk and liquidity
What a position costs to hold and to exit. Position sizing starts with the daily swing, not with conviction.
Typical daily swing (ATR)3.87%
Volume versus 20-day0.7x
Median daily turnoverRs 130.4 cr
Peers
Healthcare · 68 classified companies
WOCKPHARMA trades at 102.2× trailing earnings against an industry median of 44.7× across 65 other classified companies in its industry — more expensive than them, by 129%. A multiple is a statement about expectations, not about quality: cheap usually means the market expects less, and it is often right.
largest twelve by market capitalisation. Market cap and P/E need filed financials, so blanks are companies whose filings have not been read yet
Recent sessions
what this stock has matched since the engine went live
This is the live record, not the backtest — the scans this stock actually appeared in on each stored session. A name that keeps reappearing is in a persistent condition; a one-day appearance usually is not.
Session
Scans
Which
9 Sep
2
Closing in on a 52-week high, Growing fast and near a high
8 Sep
2
Closing in on a 52-week high, Growing fast and near a high
7 Sep
2
Closing in on a 52-week high, Growing fast and near a high